Search results for "2019"

showing 10 items of 1190 documents

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

2021

Introduction: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. Methods: A multicohort Marko…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationTreatment duration030106 microbiologyPopulationTreatment duration03 medical and health sciences0302 clinical medicineHealth careTreatment duration.Medicine030212 general & internal medicineeducationOriginal ResearchHepatitis C viruseducation.field_of_studyGlecaprevir/pibrentasvirbusiness.industryGlecaprevirPibrentasvirInfectious DiseasesItalyEmergency medicineObservational studyGlecaprevir / pibrentasvirHepatitis C virubusinessInfectious Diseases and Therapy
researchProduct

The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives

2021

INTRODUCTION: The COVID-19 pandemic has dramatically challenged the national health systems worldwide in the last months. Dalbavancin is a novel antibiotic with a long plasmatic half-life and simplified weekly administration regimens, thus representing a promising option for the outpatient treatment of Gram-positive infections and the early discharge of hospitalized patients. Dalbavancin is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Many preliminary data seem to support its use in other indications, such as osteomyelitis, prosthetic joint infections, and infective endocarditis. AREAS COVERED: A search in the literature using validated keyword…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classProsthetic joint030106 microbiologyAntibioticsGram-Positive Bacterial InfectionABSSSIsMicrobiologyDrug Administration Scheduleosteomyelitis.endocarditi03 medical and health sciencesABSSSIs; COVID-19; dalbavancin; endocarditis; Gram-positive; long-acting; osteomyelitisGram-positive0302 clinical medicineVirologyPandemicAnti-Bacterial AgentmedicineAmbulatory CareAnimalsHumans030212 general & internal medicineIntensive care medicineGram-Positive Bacterial Infectionsbusiness.industryAnimalOsteomyelitisDalbavancinCOVID-19osteomyelitisSkin Diseases Bacteriallong-actingABSSSImedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesInfective endocarditisSkin structureendocarditisosteomyelitiTeicoplaninbusinessdalbavancinHuman
researchProduct

Phage Therapy in Livestock and Companion Animals

2021

The irrational use of antibiotics has led to a high emergence of multi-drug resistant (MDR) bacteria. The traditional overuse of antibiotics in the animal feed industry plays a crucial role in the emergence of these pathogens that pose both economic and health problems. In addition, antibiotics have also recently experienced an increase to treat companion animal infections, promoting the emergence of MDR bacteria in pets, which can reach humans. Phages have been proposed as an alternative for antibiotics for the treatment of livestock and companion animal infections due to their multiple advantages as adaptative drugs, such as their ability to evolve, to multiply at the site of infections, …

0301 basic medicineMicrobiology (medical)phage therapyPhage therapyCoronavirus disease 2019 (COVID-19)Phage therapymedicine.drug_classAnimal feedVeterinary medicineCompanion animalmedicine.medical_treatment030106 microbiologyAntibioticsRM1-950ReviewBiologyAntimicrobial resistanceBiochemistryMicrobiologyantibiotics03 medical and health sciencesHealth problemsAntibiotic resistanceAntibioticsmedicinePharmacology (medical)antimicrobial resistanceGeneral Pharmacology Toxicology and Pharmaceuticsbusiness.industryBiotechnologyveterinary medicine030104 developmental biologyInfectious DiseasesLivestockTherapeutics. PharmacologybusinessAntibiotics
researchProduct

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

2020

Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of1 year. Anti- programmed cell death protein 1 (anti-PD-1) monotherapy has demonstrated modest efficacy in previously treated GEA and ESCC. In 2020, four pivotal trials have established anti-PD-1 therapy as a new standard of care for selected GEA and ESCC patients as first-line advanced and adjuvant therapy. In this review, we discuss the recent results of the CheckMate 649, ATTRACTION-4, KEYNOTE-590 and CheckMate 577 trials. We consider these results in the context of current standards …

0301 basic medicineOncologymedicine.medical_specialty2019-20 coronavirus outbreakEsophageal Neoplasmsmedicine.medical_treatmentImmune checkpoint inhibitorsFirst lineAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineStomach NeoplasmsChemoimmunotherapyInternal medicinemedicineAdjuvant therapyHumansneoplasmsGastroesophageal adenocarcinomabusiness.industryHematologyImmunotherapyEsophageal cancermedicine.diseaseCombined Modality Therapydigestive system diseasesNivolumab030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessAnnals of Oncology
researchProduct

Potential Influence of Helminth Molecules on COVID-19 Pathology

2020

In recent months, the parasitology research community has been tasked with investigation of the influence of parasite coinfection on coronavirus disease 2019 (COVID-19) outcomes. Herein, we share our approach to analyze the effect of the trematode Fasciola hepatica as a modulator of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and of COVID-19 pathology.

0301 basic medicinePathologymedicine.medical_specialtyFascioliasisCoronavirus disease 2019 (COVID-19)Helminth proteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)viruses030231 tropical medicineInfection modulation03 medical and health sciences0302 clinical medicineAntigenic ModulationPathology modulationparasitic diseasesMedicineParasite hostingFasciola hepaticaHelminthsAnimalsHumansImmunologic FactorsInflammationHelminth parasitesRespiratory Distress SyndromebiologyForumbusiness.industryCoinfectionvirus diseasesCOVID-19Helminth ProteinsFasciola hepaticamedicine.diseasebiology.organism_classificationImmunity Innate030104 developmental biologyInfectious DiseasesParasitologyCoinfectionParasitologybusinessTrends in Parasitology
researchProduct

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct

COVID 19-Induced Smell and Taste Impairments: Putative Impact on Physiology

2021

This article is part of the Research Topic "The Tribute of Physiology for the Understanding of COVID-19 Disease".; International audience; Smell and taste impairments are recognized as common symptoms in COVID 19 patients even in an asymptomatic phase. Indeed, depending on the country, in up to 85-90% of cases anosmia and dysgeusia are reported. We will review briefly the main mechanisms involved in the physiology of olfaction and taste focusing on receptors and transduction as well as the main neuroanatomical pathways. Then we will examine the current evidences, even if still fragmented and unsystematic, explaining the disturbances and mode of action of the virus at the level of the nasal …

0301 basic medicineTaste2019-20 coronavirus outbreakFood intakeCoronavirus disease 2019 (COVID-19)[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]PhysiologyAnosmiaPhysiologyfeeding behaviorOlfactionReviewlcsh:Physiologytaste03 medical and health sciences0302 clinical medicinePhysiology (medical)[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]medicinesmelllcsh:QP1-981business.industryCOVID-193. Good healthDysgeusia[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030104 developmental biologymedicine.symptomphysiopathologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionTransduction (physiology)COVID 19030217 neurology & neurosurgeryFrontiers in Physiology
researchProduct

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation InhibitorsThrombosis and haemostasis
researchProduct

Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19

2020

Since December 2019, a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly engulfed the world. Cancer patients infected with COVID-19 are considered to carry higher severity of the disease and higher mortality rate than common COVID-19 patients in previous studies. However, due to the poor clinical information on COVID-19 patients with cancer, the evidences that supported this conclusion are insufficient. At present, rather limited reports have analyzed the clinical data of breast cancer patients infected with COVID-19. Therefore, in this retrospective study, we described the clinical characteristics and the outcomes of 35 …

0301 basic medicinemedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)Diseasemedicine.disease_causelcsh:RC254-282Asymptomatic03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineclinical characteristicsCoronavirusOriginal Researchnon-cancerbusiness.industrySARS-CoV-2Mortality rateCancerRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisprognosismedicine.symptombusinessFrontiers in Oncology
researchProduct